NASDAQ:ADAP Adaptimmune Therapeutics (ADAP) Stock Price, News & Analysis $1.06 -0.05 (-4.05%) (As of 02:45 PM ET) Add Compare Share Share Today's Range$1.04▼$1.1250-Day Range$0.98▼$1.3952-Week Range$0.42▼$2.05Volume1.14 million shsAverage Volume1.76 million shsMarket Capitalization$272.36 millionP/E RatioN/ADividend YieldN/APrice Target$3.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Adaptimmune Therapeutics alerts: Email Address Adaptimmune Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside217.7% Upside$3.38 Price TargetShort InterestHealthy2.67% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.54Based on 2 Articles This WeekInsider TradingSelling Shares$22,814 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.23) to ($0.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.91 out of 5 starsMedical Sector555th out of 927 stocksBiological Products, Except Diagnostic Industry92nd out of 154 stocks 3.5 Analyst's Opinion Consensus RatingAdaptimmune Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAdaptimmune Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Adaptimmune Therapeutics' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.67% of the outstanding shares of Adaptimmune Therapeutics have been sold short.Short Interest Ratio / Days to CoverAdaptimmune Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adaptimmune Therapeutics has recently decreased by 4.21%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAdaptimmune Therapeutics does not currently pay a dividend.Dividend GrowthAdaptimmune Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADAP. Previous Next 1.4 News and Social Media Coverage News SentimentAdaptimmune Therapeutics has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Adaptimmune Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 8 people have searched for ADAP on MarketBeat in the last 30 days. This is a decrease of -47% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Adaptimmune Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -86% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adaptimmune Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,814.00 in company stock.Percentage Held by Insiders12.44% of the stock of Adaptimmune Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 31.37% of the stock of Adaptimmune Therapeutics is held by institutions.Read more about Adaptimmune Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Adaptimmune Therapeutics are expected to decrease in the coming year, from ($0.23) to ($0.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adaptimmune Therapeutics is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adaptimmune Therapeutics is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdaptimmune Therapeutics has a P/B Ratio of 6.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Adaptimmune Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. About Adaptimmune Therapeutics Stock (NASDAQ:ADAP)Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.Read More ADAP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADAP Stock News HeadlinesSeptember 12, 2024 | seekingalpha.comAdaptimmune's T-Cell Therapy Journey: A Small Market, Big AmbitionsAugust 29, 2024 | finanznachrichten.deAdaptimmune Therapeutics PLC: Adaptimmune to Participate in Two Bank Conferences this SeptemberSeptember 16, 2024 | Monetary Gold (Ad)Biden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.August 15, 2024 | markets.businessinsider.comHold Rating on Adaptimmune Amid Commercialization and Financial UncertaintiesAugust 15, 2024 | finance.yahoo.comAdaptimmune Therapeutics (NASDAQ:ADAP) investors are sitting on a loss of 74% if they invested three years agoAugust 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Adaptimmune Therapeutics Amidst Promising Product Launch and Strong PipelineAugust 13, 2024 | msn.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Q2 2024 Earnings Call TranscriptAugust 12, 2024 | markets.businessinsider.comBuy Rating Justified by Adaptimmune’s Promising Financials and Strong Product Launch ProspectsSeptember 16, 2024 | Monetary Gold (Ad)Biden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.August 12, 2024 | seekingalpha.comAdaptimmune Therapeutics plc (ADAP) Q2 2024 Earnings Call TranscriptAugust 12, 2024 | markets.businessinsider.comADAP Stock Earnings: Adaptimmune Therapeutics Beats EPS, Beats Revenue for Q2 2024August 12, 2024 | finance.yahoo.comBP_CCB RP1911F (66756.HK)August 9, 2024 | finance.yahoo.comAdaptimmune leads in soft tissue sarcoma therapy with first TCR approvalAugust 8, 2024 | bizjournals.comSeed Therapeutics enters into collaboration deal valued at up to $1.5B with Japan-based EisaiAugust 7, 2024 | markets.businessinsider.comOutperform Rating Affirmed for Adaptimmune Following FDA Approval and Positive Market Outlook for TecelraAugust 5, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Lantheus (LNTH) and Vertex Pharmaceuticals (VRTX)August 2, 2024 | msn.comAdaptimmune granted FDA accelerated nod for lead assetAugust 2, 2024 | msn.comFDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A DecadeSee More Headlines Receive ADAP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/16/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADAP CUSIPN/A CIK1621227 Webwww.adaptimmune.com Phone441235430000Fax44-12-3543-0001Employees490Year FoundedN/APrice Target and Rating Average Stock Price Target$3.38 High Stock Price Target$4.00 Low Stock Price Target$3.00 Potential Upside/Downside+208.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-113,870,000.00 Net Margins-51.25% Pretax Margin-50.49% Return on Equity-116.80% Return on Assets-25.02% Debt Debt-to-Equity Ratio0.26 Current Ratio3.09 Quick Ratio3.09 Sales & Book Value Annual Sales$60.28 million Price / Sales4.65 Cash FlowN/A Price / Cash FlowN/A Book Value$0.17 per share Price / Book6.45Miscellaneous Outstanding Shares255,740,000Free Float216,120,000Market Cap$280.29 million OptionableOptionable Beta2.21 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Adrian G. Rawcliffe (Age 52)CEO, Principal Accounting Officer & Director Comp: $693.64kMr. Gavin Hilary James Wood ACA (Age 54)BA (Hons), Chief Financial Officer Comp: $508.22kMr. William C. Bertrand Jr. (Age 59)Esq., J.D., Chief Operating Officer Comp: $573.8kDr. Elliot Norry B.A. (Age 60)M.D., Chief Medical Officer Comp: $549.05kMs. Cintia Piccina Pharm.D. (Age 50)Chief Commercial Officer Comp: $597.44kDr. Helen Katrina Tayton-Martin MBA (Age 57)Ph.D., Co-Founder & Chief Business & Strategy Officer Comp: $709.84kMs. Joanna Brewer Ph.D. (Age 48)Chief Scientific Officer Dr. Juli P. Miller Ph.D.VP of Corporate Affairs & Investor RelationsMs. Kerry SharpSenior VP & General CouncilDana LynchSenior Director of Corporate CommunicationsMore ExecutivesKey CompetitorsPrecigenNASDAQ:PGENCellectisNASDAQ:CLLSFate TherapeuticsNASDAQ:FATEbluebird bioNASDAQ:BLUEAtara BiotherapeuticsNASDAQ:ATRAView All CompetitorsInsiders & InstitutionsLong Focus Capital Management LLCBought 1,662,184 shares on 8/15/2024Ownership: 5.002%Marshall Wace LLPSold 109,133 shares on 8/14/2024Ownership: 0.059%Renaissance Technologies LLCBought 394,566 shares on 8/9/2024Ownership: 0.724%Baillie Gifford & Co.Sold 722,672 shares on 7/25/2024Ownership: 6.138%Cintia PiccinaSold 24,531 sharesTotal: $22,813.83 ($0.93/share)View All Insider TransactionsView All Institutional Transactions ADAP Stock Analysis - Frequently Asked Questions How have ADAP shares performed this year? Adaptimmune Therapeutics' stock was trading at $0.7930 at the beginning of 2024. Since then, ADAP shares have increased by 34.3% and is now trading at $1.0650. View the best growth stocks for 2024 here. How were Adaptimmune Therapeutics' earnings last quarter? Adaptimmune Therapeutics plc (NASDAQ:ADAP) announced its quarterly earnings data on Monday, August, 12th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter. The biotechnology company had revenue of $128.23 million for the quarter, compared to analyst estimates of $58 million. Adaptimmune Therapeutics had a negative net margin of 51.25% and a negative trailing twelve-month return on equity of 116.80%. When did Adaptimmune Therapeutics IPO? Adaptimmune Therapeutics (ADAP) raised $150 million in an initial public offering on Wednesday, May 6th 2015. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager. Who are Adaptimmune Therapeutics' major shareholders? Top institutional investors of Adaptimmune Therapeutics include Baillie Gifford & Co. (6.14%), Long Focus Capital Management LLC (5.00%), Renaissance Technologies LLC (0.72%) and Marshall Wace LLP (0.06%). Insiders that own company stock include Gavin Wood, Garry E Menzel, Cintia Piccina, Adrian Rawcliffe, William C Bertrand Jr, John Lunger and Elliot Norry. View institutional ownership trends. How do I buy shares of Adaptimmune Therapeutics? Shares of ADAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Adaptimmune Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), Brainstorm Cell Therapeutics (BCLI), Second Sight Medical Products (EYES), Shopify (SHOP) and Micron Technology (MU). This page (NASDAQ:ADAP) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | SponsoredBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.